[go: up one dir, main page]

RS56738B1 - Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu - Google Patents

Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu

Info

Publication number
RS56738B1
RS56738B1 RS20180016A RSP20180016A RS56738B1 RS 56738 B1 RS56738 B1 RS 56738B1 RS 20180016 A RS20180016 A RS 20180016A RS P20180016 A RSP20180016 A RS P20180016A RS 56738 B1 RS56738 B1 RS 56738B1
Authority
RS
Serbia
Prior art keywords
oral
dosage unit
solid dosage
unit containing
estetrol component
Prior art date
Application number
RS20180016A
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Donesta Bioscience B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56738(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donesta Bioscience B V filed Critical Donesta Bioscience B V
Publication of RS56738B1 publication Critical patent/RS56738B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20180016A 2013-12-12 2014-12-10 Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu RS56738B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196904 2013-12-12
PCT/EP2014/077127 WO2015086643A1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component
EP14814804.2A EP3079671B1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component

Publications (1)

Publication Number Publication Date
RS56738B1 true RS56738B1 (sr) 2018-03-30

Family

ID=49759137

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180016A RS56738B1 (sr) 2013-12-12 2014-12-10 Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu

Country Status (30)

Country Link
US (2) US9884064B2 (sr)
EP (1) EP3079671B1 (sr)
JP (1) JP6447931B2 (sr)
KR (1) KR102265150B1 (sr)
CN (1) CN105979935B (sr)
AU (1) AU2014363599B2 (sr)
BR (1) BR112016013502B1 (sr)
CA (1) CA2932855C (sr)
CL (1) CL2016001411A1 (sr)
CY (1) CY1119817T1 (sr)
DK (1) DK3079671T3 (sr)
EA (1) EA032306B1 (sr)
ES (1) ES2655076T3 (sr)
HR (1) HRP20180129T1 (sr)
HU (1) HUE035848T2 (sr)
IL (1) IL246082B (sr)
LT (1) LT3079671T (sr)
MA (1) MA39105B1 (sr)
MX (1) MX369035B (sr)
NO (1) NO3079671T3 (sr)
NZ (1) NZ720906A (sr)
PL (1) PL3079671T3 (sr)
PT (1) PT3079671T (sr)
RS (1) RS56738B1 (sr)
SG (1) SG11201604741UA (sr)
SI (1) SI3079671T1 (sr)
SM (1) SMT201700582T1 (sr)
TN (1) TN2016000230A1 (sr)
WO (1) WO2015086643A1 (sr)
ZA (1) ZA201603903B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2714712T1 (sl) 2011-06-01 2016-11-30 Estetra S.P.R.L. Postopek za proizvodnjo intermediatov estetrola
KR101994805B1 (ko) 2011-06-01 2019-07-01 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PT2741824T (pt) * 2011-08-11 2017-07-06 Estetra Sprl Utilização de estetrol como contracetivo de emergência
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
LT3106148T (lt) * 2015-06-18 2018-06-25 Mithra Pharmaceuticals S.A. Burnoje disperguojamos dozės vienetas, turintis estetrolio komponentą
ES2877186T3 (es) * 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
US11147771B2 (en) * 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) * 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
GEP20227407B (en) 2018-02-07 2022-08-25 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
CN116355031A (zh) * 2019-09-27 2023-06-30 工业化学有限公司 制备(15α,16α,17β)-雌-1,3,5(10)-三烯-3,15,16,17-四醇一水合物(雌四醇一水合物)的工艺
MX2023003432A (es) 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
WO2024160373A1 (en) 2023-02-02 2024-08-08 Industriale Chimica S.R.L. PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
DK1390040T3 (da) * 2001-05-18 2007-04-23 Pantarhei Bioscience Bv Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DE60223795T2 (de) * 2001-05-23 2008-11-27 Pantarhei Bioscience B.V. Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
US7871995B2 (en) * 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP1446128B1 (en) 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
KR100936827B1 (ko) * 2002-02-21 2010-01-14 바이엘 쉐링 파마 악티엔게젤샤프트 하나 이상의 스테로이드, 하나 이상의테트라히드로폴레이트 성분 및 비타민 b12를 포함하는제약 조성물
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
ES2659316T3 (es) * 2006-06-08 2018-03-14 Allergan Pharmaceuticals International Limited Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
EP2086550A2 (en) * 2006-11-29 2009-08-12 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
ES2531929T3 (es) * 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
EP2117518A2 (en) * 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
US8367647B2 (en) 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
DE102009007771B4 (de) * 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) * 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens

Also Published As

Publication number Publication date
MA39105A1 (fr) 2017-04-28
NO3079671T3 (sr) 2018-03-24
CY1119817T1 (el) 2018-06-27
WO2015086643A1 (en) 2015-06-18
SMT201700582T1 (it) 2018-03-08
CN105979935A (zh) 2016-09-28
MX2016007595A (es) 2016-11-28
MA39105B1 (fr) 2018-05-31
BR112016013502B1 (pt) 2021-05-11
HUE035848T2 (en) 2018-05-28
KR102265150B1 (ko) 2021-06-16
NZ720906A (en) 2022-04-29
EA201691226A1 (ru) 2016-10-31
US20160310506A1 (en) 2016-10-27
EP3079671A1 (en) 2016-10-19
DK3079671T3 (en) 2017-12-11
CL2016001411A1 (es) 2016-11-11
TN2016000230A1 (en) 2017-10-06
JP2016540021A (ja) 2016-12-22
SG11201604741UA (en) 2016-07-28
PT3079671T (pt) 2017-11-24
JP6447931B2 (ja) 2019-01-09
MX369035B (es) 2019-10-25
EP3079671B1 (en) 2017-10-25
AU2014363599A1 (en) 2016-06-30
EA032306B1 (ru) 2019-05-31
IL246082B (en) 2018-03-29
IL246082A0 (en) 2016-07-31
ES2655076T3 (es) 2018-02-16
HRP20180129T1 (hr) 2018-02-23
KR20160102212A (ko) 2016-08-29
ZA201603903B (en) 2018-07-25
BR112016013502A2 (pt) 2018-07-03
AU2014363599B2 (en) 2019-10-31
CA2932855C (en) 2022-07-19
SI3079671T1 (en) 2018-04-30
US9987287B2 (en) 2018-06-05
US9884064B2 (en) 2018-02-06
CA2932855A1 (en) 2015-06-18
PL3079671T3 (pl) 2018-03-30
CN105979935B (zh) 2019-07-26
US20180117063A1 (en) 2018-05-03
LT3079671T (lt) 2018-02-12

Similar Documents

Publication Publication Date Title
RS56738B1 (sr) Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu
HRP20180635T1 (hr) Pirazolamidni spoj i njegova upotreba u medicini
SG10201708409VA (en) Medicament device
DK3310333T3 (da) Oralt dispergibel doseringsenhed indeholdende en estetrolkomponent
HK1215191A1 (zh) 低劑量醫藥組合物
HK1223833A1 (zh) 藥物劑型
PL2983650T3 (pl) Doustna kompozycja farmaceutyczna zawierająca N-acetylocysteinę o zamaskowanym smaku
GB201305103D0 (en) An oral dosage form
DK2953577T3 (da) Engangsspytejektor til anvendelse i tandpleje
GB2520315B (en) Oral Syringes
LT2988782T (lt) Dozavimo formos, skirtos peroraliniam veikliųjų medžiagų vartojimui
TH1401004646B (th) องค์ประกอบทางเภสัชกรรมชนิดรับประทาน
TH148804B (th) สูตรยาที่ใช้รับประทานที่ประกอบรวมด้วยลานโซพราโซล (Laxoprazole) และวิธีการเตรียมสิ่งดังกล่าว
GB201309971D0 (en) Oral medicines syringe